Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |